
12+ companies advance IgE receptor antagonists pipeline targeting allergic diseases with new therapies nearing market.
DelveInsight reports over 12 companies developing IgE receptor antagonists for allergic conditions like asthma and chronic urticaria. Key drugs such as ADL-018 and LP-003 are in late-stage trials, showing promise against existing treatments like Xola...


